Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Development and initial validation of a scale assessing sources of decision hesitation in patients with lung cancer invited to participate in drug clinical trials.

Created on 30 Jun 2026

Authors

Yueting Huang, Wanzhen Li, Weilin Zhang

Published in

Asia-Pacific journal of oncology nursing. Volume 13. Pages 100985. Epub May 29, 2026.

Abstract

To develop and preliminarily validate a theory-driven, nursing-relevant scale measuring sources of decision hesitation for patients with lung cancer who have been invited to participate in drug clinical trials.
A two-stage cross-sectional study was conducted between April 2024 and September 2025. The initial item pool was established via literature review and semi-structured patient interviews. Two rounds of Delphi consultation and pre-testing were conducted to form the preliminary scale. A total of 407 eligible patients with lung cancer from a tertiary hospital in Sichuan were enrolled. Exploratory and confirmatory factor analyses, correlation analysis and reliability tests were performed to verify scale psychometric properties.
The final 23-item scale captures six key sources of decision hesitation: perceived trial risk, perceived trial value, perceived patient-physician trust, perceived family influence, perceived resource barriers, and perceived self-efficacy. The six-factor model showed acceptable fit indices. The scale demonstrated good content validity (scale-level content validity index [S-CVI] = 0.97), convergent validity (r = 0.471 with the Decisional Conflict Scale), internal consistency (Cronbach's α = 0.929), and test-retest reliability (intraclass correlation coefficient [ICC] = 0.779).
This study provides initial psychometric evidence for a scale capturing six key sources of decision hesitation among patients with lung cancer invited to participate in drug clinical trials. The scale shows promise as a screening and supportive assessment tool; however, further prospective, multicenter validation is required to confirm its predictive validity and generalizability.
This study was registered with the China Clinical Trial Registry (Registration No. ChiCTR2400093749).

PMID:
42376612
Bibliographic data and abstract were imported from PubMed on 30 Jun 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement